Anticancer agent 267

Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC50 for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models[1].

Product Specifications

UNSPSC

12352005

Target

Mixed Lineage Kinase; Necroptosis; RIP kinase

Related Pathways

Apoptosis; MAPK/ERK Pathway

Field of Research

Cancer

Smiles

O=C(C(N/N=C/C1=CC=C([N+]([O-])=O)S1)=O)NCC2=CC=CC=N2

Molecular Formula

C13H11N5O4S

Molecular Weight

333.32

References & Citations

[1]Akhavan R, et al., Discovery of a new hydrazone-oxamide hybrid capable of inducing necroptotic cell death in triple negative breast cancer cells. Bioorg Chem. 2025 Apr;157:108267.